Copiktra (duvelisib)

NOW APPROVED

The FIRST AND ONLY oral dual PI3K-δ and PI3K-γ inhibitor that targets malignant B cells and the tumor microenvironment.1,2

COPIKTRA is a kinase inhibitor indicated for the treatment of adult patients with1:

Relapsed or refractory CLL or SLL after at least 2 prior therapies

Relapsed or refractory FL after at least 2 prior systemic therapies
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

CLL, chronic lymphocytic leukemia; FL, follicular lymphoma; PI3K, phosphoinositide 3-kinase; SLL, small lymphocytic lymphoma.

Request to be contacted by an Oncology Account Manager for more information about COPIKTRA.

* required
Please complete all of the required fields to request a representative.
BY CLICKING REQUEST, I understand and agree to the Verastem Oncology Terms of Use and Privacy Policy.
I also agree to receive future communications from Verastem Oncology.
* required
Please complete all of the required fields to request a representative.